Lessons from the p53 mutant mouse

Journal of Cancer Research and Clinical Oncology

Volumn 122, Issue 6, 1996, Pages 319-327

  Jacks, Tyler ^a  

^a HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

Apoptosis; Cancer genetics; Gene targeting; Mouse knockouts; p53; Tumor suppressor genes

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; PROTEIN P53;

ANIMAL MODEL; APOPTOSIS; CANCER GENETICS; DRUG RESISTANCE; GENE MUTATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR SUPPRESSOR GENE;

ANIMALS; GENES, P53; MICE; MICE, MUTANT STRAINS; MUTATION;

EID: 0029967219     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01220798     Document Type: Review

References (79)

1. Armstrong JF, Kaufman MH, Harrison DJ, Clarke AR (1995) High-frequency developmental abnormalities in p53-deficient mice. Curr Biol 5:937-943
2. Bardeesy N, Falkoff D, Petruzzi MJ, Nowak N, Zabel B, Adam M, Aguiar MC, Grundy P, Shows T, Pelletier J (1994) Anaplastic Wilms' tumour, a subtype displaying poor prognosis, harbors p53 gene mutations. Nat Genet 7:91-97
3. Brannan CI, Perkins AS, Vogel KS, Ratner N, Nordlund ML, Reid SW, Buchberg AM, Jenkins NA, Parada LF, Copeland NG (1994) Targeted disruption of the neurofibromatosis type-1 gene leads to developmental abnormalities in heart and various neural crest-derived tissues. Genes Dev 8:1019-1029
4. Brugarolas J, Chandrasekaran C, Gordon JI, Beach D, Jacks T, Hannon G (1995) Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 377:552-557
5. Caelles C, Helmberg A , Karin M (1994) p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature 370:220-223
6. Cho KR, Fearon ER (1995) DCC:linking tumor suppressor genes and altered cell surface interactions in cancer? Curr Opin Genet Dev 5:72-78
7. Clarke AR, Maandag ER, Roon M van, Lugt NMT van der, Valk M van der, Hooper ML, Berns A, Riele H te (1992) Requirement for a functional Rb-1 gene in murine development. Nature 359:328-330
8. Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML, Wyllie AH (1993) Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362:849-852
9. Debbas M, White E (1993) Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B. Genes Dev 7:546-554
10. CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 82:675-684
11. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA, Butel JS, Bradley A (1992) Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356:215-221
12. Donehower LA, Godley LA, Aldaz CM, Pyle R, Shi Y-P, Pinkel D, Gray J, Bradley A, Medina D, Varmus HE (1995) Deficiency of p53 accelerates mammary tumorigenesis in Wnt-1 transgenic mice and promotes chromosomal instability. Genes Dev 9:882-895
13. Duan DR, Pause A, Burgess WH, Aso T, Chen DYT, Garrett KP, Conaway RC, Conaway JW, Linehan WM, Klausner RD (1995) Inhibition of transcriptional elongation by the VHL tumor suppressor protein. Science 269:1402-1406
14. Dutta A, Ruppert JM, Aster JC, Winchester E (1993) Inhibition of DNA replication factor RPA by p53. Nature 365:79-82
15. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler K, Vogelstein B (1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825
16. Fodde R, Edelman W, Yang K, Leeuwen C van, Carlson C, Renault B, Breukel C, Alt E, Lipkin M, Khan PM, Kucherlapati R (1994) A targeted chain-termination in the mouse Apc gene results in multiple intestinal tumors. Proc Natl Acad Sci USA 91: 8969-8973
17. Ginsberg D, Mechta F, Yaniv M, Oren M (1991) Wild-type p53 can down-modulate the activity of various promoters. Proc Natl Acad Sci USA 88:9979-9983
18. Greenblatt MS, Bennett WP, Hollstein M, Harris CC (1994) Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54: 4855-4878
19. Harrison DJ, Hooper ML, Armstrong JF, Clarke AR (1995) Effects of heterozygosity for the Rb-1t19neo allele in the mouse. Oncogene 10:1615-1620
20. Harvey M, McArthur MJ, Montgomery CA, Butel JS, Bradley A, Donehower LA (1993) Spontaneous and carcinogen-induced tumors in p53-deficient mice. Nat Genet 5:225-229
21. Hastie ND (1994) The genetics of Wilms' tumor - a case of disrupted development. Annu Rev Genet 28:523-558
22. Haupt Y, Rowan S, Shaulian E, Vousden KH, Oren M (1995) Induction of apoptosis in HeLa cells by trans-activation-deficient p53. Genes Dev 9:2170-2183
23. Hermeking H, Eick D (1994) Mediation of c-myc-induced apoptosis by p53. Science 265:2091-2093
24. Howes KA, Ransom N, Papermaster DS, Lasudry JGH, Albert DM, Windle JJ (1994). Apoptosis or retinoblastoma: alternative fates of photoreceptors expressing the HPV-16 E7 gene in the presence or absence of p53. Genes Dev 8:1300-1310
25. Hu N, Gutsmann A, Herbert DC, Bradley A, Lee WH, Lee EY-HP (1994) Heterozygous Rb-1 delta 20/+ mice are predisposed to tumors of the pituitary gland with a nearly complete penetrance. Oncogene 9:1021-1027
26. Jacks T, Fazeli A, Schmitt E, Bronson R, Goodell M, Weinberg R (1992) Effects of an Rb mutation in the mouse. Nature 359: 295-300
27. Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT, Weinberg RA (1994a) Tumor spectrum analysis in p53-mutant mice. Curr Biol 4:1-7
28. Jacks T, Shih TS, Schmitt EM, Bronson RD, Bernards A, Weinberg RA (1994b) Tumourigenic and developmental consequences of a targeted Nf1 mutation in the mouse. Nat Genet 7:353-361
29. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stocken E, Day RS3, Johnson BE, Skolnick MH (1994) A cell cycle regulator potentially involved in genesis of many tumor types. Science 264:436-440
30. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW (1991) Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51:6304-6311
31. Kastan M, Zhan Q, El-Deiry WS, Carrier F, Jacks T, Walsh WV, Plunkett BS, Vogelstein B, Fornace AJ Jr (1992) A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71:587-597
32. Kemp CJ, Wheldon T, Balmain A. (1994) p53-deficient mice are extremely susceptible to radiation-induced tumorigenesis. Nat Genet 8:66-69.
33. Kern SE, Kinzler KW, Bruskin A, Jarosz D, Friedman P, Prives C, Vogelstein B (1991) Identification of p53 as a sequence-specific DNA binding protein. Science 252:1708-1711
34. Kibel A, Iliopaoulos O, DeCaprio JA, Kaelin WG (1995) Binding of the von-Hippel-Lindau tumor suppressor protein to Elongin B and C. Science 269:1444-1446
35. Kley N, Chung RY, Fay S, Loeffler JP, Seizinger BR (1992) Repression of the basal c-fos promoter by wild-type p53. Nucleic Acids Res 20:4083-4087
36. Knudson JAG (1971) Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 68:820-823
37. Kreidberg JA, Sariola H, Loring JM, Maeda M, Pelletier J, Housman D, Jaenisch R (1993) WT-1 is required for early kidney development. Cell 74:679-691
38. Kuhn R, Schwenk F, Aguet M, Rajewsky K (1995) Inducible gene targeting in mice. Science 269:1427-1429
39. Lane DP (1992) p53, guardian of the genome. Nature 358:15-16
40. Lee EY-HP, Chang C-Y, Hu N, Wang Y-CJ, Lai C-C, Herrup K, Lee W-H (1992) Mice deficient for Rb are nonviable and show defects in neurogenesis and haematopoiesis. Nature 359: 288-295.
41. Livingstone LR, White A, Sprouse J, Livanos E, Jacks T, Tlsty TD (1992) Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 70:923-935
42. Lowe SW, Ruley HE (1993) Stabilization of the p53 tumor suppressor is induced by adenovirus-5 E1A and accompanies apoptosis. Genes Dev 7:535-545
43. Lowe SM, Ruley HE, Jacks T, Housman DE (1993a) p53-dependent apoptosis modulates the cytoxicity of anticancer agents. Cell 74:957-967
44. Lowe SW, Schmitt ES, Smith SW, Osborne BA, Jacks T (1993b) p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362:847-849.
45. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T (1994a) p53 status and the efficacy of cancer therapy in vivo. Science 266:807-810
46. Lowe SW, Jacks T, Housman DE, Ruley HE (1994b) Abrogation of oncogene-associated apoptosis allows transformation of p53-deficient cells. Proc Nat Acad Sci USA 91:2026-2030
47. Mack DH, Vartikar J, Pipas JM, Laimins LA (1993) Specific repression of TATA-mediated but not intiator-mediated transcription by wild-type p53. Nature 363:281-283
48. Malkin D (1993) p53 and the Li-Fraumeni syndrome. Cancer Genet Cytogenet 66:83-92
49. McCormick F (1995) Ras signaling and NF1. Curr Opin Genet Dev 5:51-55
50. Merritt AJ, Potten CS, Kemp CJ, Hickman JA, Balmain A, Lane D, Hall PA (1994) The role of p53 in spontaneous and radiation-induced apoptosis in the gastrointestinal tract of normal and p53-deficient mice. Cancer Res 54:614-617
51. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, et al. (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66-71
52. Miyaki M, Tanaka K, Kikuchi-Yanoshita R, Muraoka M, Konishi M (1995) Familial polyposis: recent advances. Crit Rev Oncol Hematol 19:1-31
53. Miyashita T, Reed JC (1995) Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80:293-299
54. Moran E (1993) DNA tumor virus transforming proteins and the cell cycle. Curr Opin Genet Dev 3:63-70
55. Morgenbesser SD, Williams BO, Jacks T, DePinho RA (1994) p53-dependent apoptosis produced by Rb-deficiency in the developing mouse lens. Nature 371:72-74
56. Moser AR, Pilot HC, Dove WF (1990) A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science 247:322-324
57. Okamoto K, Beach D (1994) Cyclin G is a transcriptional target of the tumor suppressor protein p53. EMBO J 13:4816-4823
58. Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris S, Kinnzler KW, Vogelstein B (1993) Oncoprotein mdm2 conceals the activation domain of tumor suppressor p53. Nature 362:857-860
59. Pan H, Griep A (1994) Altered cell cycle regulation in the lens of HPV-16 E6 or E7 transgenic mice: implications for tumor suppressor gene function in development. Genes Dev 8:1285-1299
60. Pan H, Griep AE (1995) Temporally distinct patterns of p53-dependent and p53-independent apoptosis during mouse lens development. Genes Dev 9:2157-2169
61. Polakis P (1995) Mutations in the APC gene and their implications for protein structure and function. Curr Opin Genet Dev 5:66-71
62. Purdie CA, Harrison DJ, Peter A, Dobbie L, White S, Howie SEM, Salter DM, Bird CC, Wyllie AH, Hooper ML, Clarke AR (1994) Tumour incidence, spectrum and ploidy in mice with a large deletion in the p53 gene. Oncogene 9:603-609
63. Sabbatini P, Lin J, Levine AJ, White E (1995) Essential role for p53-mediated transcription in E1A-induced apoptosis. Genes Dev 9:2184-2192
64. Sah VP, Attardi LD, Mulligan GJ, Williams BO, Bronson RT, Jacks T (1995) A subset of p53-deficient embryos exhibit exencephaly. Nat Genet 10:175-180
65. Santhanam U, Ray A, Sehgal PB (1991) Reppression of the interleukine 6 promoter by p53 and the retinoblastoma susceptibility gene product. Proc Natl Acad Sci USA 88: 7605-7609
66. Savitsky K, et al. (1995) A single ataxia telangiectasia gene with a product similar to P1-3 kinase. Science 268:1749-1753
67. Strasser A, Harris AW, Jacks T, Cory S (1994) DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2. Cell 79:329-339
68. Su L-K, Kinzler KW, Vogelstein B, Preisinger AC, Moser AR, Luongo C, Gould KA, Dover WF (1992) Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science 256:668-670
69. Symonds H, Krall L, Remington L, Saenz-Robles M, Lowe S, Jacks T, Van Dyke T (1994) p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell 78:703-711
70. Tanaka N, Ishihara M, Kitagawa M, Harada H, Kimura T, Matsuyama T, Lamphier MS, Aizawa S, Mak TW, Taniguchi T (1994) Cellular commitment to oncogene-induced transformation or apoptosis is dependent on the transcription factor IRF-1. Cell 77:829-839
71. Trofatter JA, MacCollin MM, Rutter JL, Murrell JR, Duyao MP, Parry DM, Eldridge R, Kley N, Menon AG, Pulaski K, Haase VH, Ambrose CM, Munroe D, Bove C, Maines JL, Martuza RL, MacDonald ME, Deizinger BR, Short MP, Buckler AJ, Gusella JF (1993) A novel moresin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 72:791-800
72. Tsukada T, Tomooka Y, Takai S, Ueda Y, Nishikawa S, Yagi T, Tokunaga T, Takeda N, Suda Y, Abe S, Matsuo I, Ikawa Y, Aizawa S (1994) Enhanced cell proliferative potential in culture of cells from p53-deficient mice. Oncogene 9:603-609
73. Viskochil D, White R, Cawthon R (1993) The neurofibromatous type I gene. Annu Rev Neurosci 16:183-205
74. Wagner AJ, Kokontis JM, Hay N (1994) myc-mediated apoptosis requires wild-type p53 in a manner independent of cell cycle arrest and the ability of p53 to induce p21 waf1/cip1. Genes Dev 8:2817-2830
75. Wang XW, Forrester K, Yeh H, Feitelson MA, Gu JR, Harris CC (1994) Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity and association with ERCC3. Proc Natl Acad Sci USA 91:2230-2234
76. Weinberg RA (1995) The retinoblastoma protein and cell cycle control. Cell 81:323-330
77. Williams BO, Remington L, Albert DM, Mukai S, Bronson RT, Jacks T (1994) Cooperative tumorigenic effects of germline mutations in Rb and p53. Nat Genet 7:480-484
78. Yin Y, Tainksy MA, Bischoff FZ, Strong LC, Wahl GM (1992) Wild-type p53 restores cells cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 70: 937-948
79. Ziegler A, Jonason AS, Leffell DJ, Simon JA, Sharma HW, Limmelman J, Remington L, Jacks T, Brash DE (1994) Sunburn and p53 in the onset of skin cancer. Nature 372:773-776